Mentice AB

ST:MNTC Sweden Medical Devices
Market Cap
$33.60 Million
Skr376.88 Million SEK
Market Cap Rank
#26584 Global
#350 in Sweden
Share Price
Skr13.40
Change (1 day)
-1.83%
52-Week Range
Skr9.00 - Skr22.90
All Time High
Skr184.50
About

Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedura… Read more

Mentice AB (MNTC) - Net Assets

Latest net assets as of September 2025: Skr125.99 Million SEK

Based on the latest financial reports, Mentice AB (MNTC) has net assets worth Skr125.99 Million SEK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr278.51 Million) and total liabilities (Skr152.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr125.99 Million
% of Total Assets 45.24%
Annual Growth Rate 16.73%
5-Year Change -12.0%
10-Year Change N/A
Growth Volatility 32.89

Mentice AB - Net Assets Trend (2017–2024)

This chart illustrates how Mentice AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Mentice AB (2017–2024)

The table below shows the annual net assets of Mentice AB from 2017 to 2024.

Year Net Assets Change
2024-12-31 Skr143.66 Million -9.63%
2023-12-31 Skr158.97 Million -2.25%
2022-12-31 Skr162.63 Million +18.81%
2021-12-31 Skr136.89 Million -16.15%
2020-12-31 Skr163.25 Million +30.85%
2019-12-31 Skr124.77 Million +86.94%
2018-12-31 Skr66.74 Million +37.21%
2017-12-31 Skr48.64 Million --

Equity Component Analysis

This analysis shows how different components contribute to Mentice AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 267.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr1.28 Million 0.89%
Other Comprehensive Income Skr664.00K 0.46%
Other Components Skr201.73 Million 140.42%
Total Equity Skr143.66 Million 100.00%

Mentice AB Competitors by Market Cap

The table below lists competitors of Mentice AB ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mentice AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 158,973,000 to 143,663,000, a change of -15,310,000 (-9.6%).
  • Net loss of 18,420,000 reduced equity.
  • Other comprehensive income increased equity by 2,094,999.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-18.42 Million -12.82%
Other Comprehensive Income Skr2.09 Million +1.46%
Other Changes Skr1.02 Million +0.71%
Total Change Skr- -9.63%

Book Value vs Market Value Analysis

This analysis compares Mentice AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.39x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 6.65x to 2.39x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 Skr2.01 Skr13.40 x
2018-12-31 Skr2.76 Skr13.40 x
2019-12-31 Skr6.38 Skr13.40 x
2020-12-31 Skr6.72 Skr13.40 x
2021-12-31 Skr5.53 Skr13.40 x
2022-12-31 Skr6.45 Skr13.40 x
2023-12-31 Skr6.22 Skr13.40 x
2024-12-31 Skr5.62 Skr13.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mentice AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -12.82%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -6.34%
  • • Asset Turnover: 0.90x
  • • Equity Multiplier: 2.25x
  • Recent ROE (-12.82%) is below the historical average (-4.55%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 12.71% 5.67% 1.16x 1.93x Skr1.32 Million
2018 30.19% 12.83% 1.20x 1.96x Skr13.47 Million
2019 -16.51% -13.79% 0.80x 1.50x Skr-33.08 Million
2020 -8.02% -9.52% 0.56x 1.50x Skr-29.42 Million
2021 -21.32% -15.77% 0.71x 1.91x Skr-42.88 Million
2022 -18.86% -14.07% 0.65x 2.05x Skr-46.93 Million
2023 -1.77% -1.03% 0.85x 2.03x Skr-18.71 Million
2024 -12.82% -6.34% 0.90x 2.25x Skr-32.79 Million

Industry Comparison

This section compares Mentice AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $75,200,026
  • Average return on equity (ROE) among peers: -74.39%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Mentice AB (MNTC) Skr125.99 Million 12.71% 1.21x $15.67 Million
Acarix A/S (ACARIX) $76.60 Million -60.65% 0.08x $28.86 Million
Arcoma AB (ARCOMA) $12.52 Million -92.85% 4.66x $8.93 Million
Bactiguard Holding AB (publ) (BACTI-B) $353.18 Million -39.18% 0.87x $19.20 Million
CellaVision AB (CEVI) $20.07 Million 13.08% 1.20x $262.59 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $65.69 Million -72.50% 0.20x $13.78 Million
Chordate Medical Holding AB (CMH) $38.95 Million -55.88% 0.13x $17.64K
Coala Life Group AB (COALA) $52.33 Million -287.99% 0.53x $468.93K
C-Rad AB (publ) (CRAD-B) $93.64 Million 22.63% 0.57x $56.67 Million
Duearity AB (DEAR) $-2.39 Million 0.00% 0.00x $34.43K
Episurf Medical AB (publ) (EPIS-B) $41.40 Million -170.53% 0.39x $5.40 Million